BioAgilytix Presents: Total Antibody Assays for AAV-Based Gene Therapies – To Bridge or Not to Bridge

Dec 06, 2021

Virtual Seminar

Posted by BioAgilytix Labs

Register Offsite
Add to Calendar + 2021-12-06 11:00 2021-12-06 12:00 America/New_York BioAgilytix Presents: Total Antibody Assays for AAV-Based Gene Therapies – To Bridge or Not to Bridge

Assessing humoral immunogenicity is an interesting challenge for adeno-associated virus (AAV)-based gene therapies. While most people are concerned about how to deal with pre-existing antibodies and their impact on cutpoints — such as using total antibody or neutralizing antibodies for inclusion/exclusion, including/excluding based on these results, and a number of other concerns — often times just coming up with the right assay format for measuring these antibodies is overlooked.

The goal of this webinar is to provide case studies for the two typically used assay formats for measuring total antibodies (direct and bridging) and discuss the challenges and rationales for using each of them in the AAV immunogenicity space. The case studies will be followed by a panel discussion with an expert scientific team to take questions and discuss other possibilities for assay format selection.

Register for this webinar to learn about the rationale behind choosing an assay format for total antibody (TAb) assays for AAV-based gene therapies, including the pros and cons of each format.

Speakers

Jim McNally, Ph.D., Chief Scientific Officer, BioAgilytix (Moderator)

Jay Stringer, Ph.D., Manager I, BioAgilytix

Luke Armstrong, Ph.D., Manager II, BioAgilytix

Todd Lester, Associate Director, BioAgilytix

Xiaoxi Yang, Ph.D., Manager I, BioAgilytix

Virtual Seminar

Assessing humoral immunogenicity is an interesting challenge for adeno-associated virus (AAV)-based gene therapies. While most people are concerned about how to deal with pre-existing antibodies and their impact on cutpoints — such as using total antibody or neutralizing antibodies for inclusion/exclusion, including/excluding based on these results, and a number of other concerns — often times just coming up with the right assay format for measuring these antibodies is overlooked.

The goal of this webinar is to provide case studies for the two typically used assay formats for measuring total antibodies (direct and bridging) and discuss the challenges and rationales for using each of them in the AAV immunogenicity space. The case studies will be followed by a panel discussion with an expert scientific team to take questions and discuss other possibilities for assay format selection.

Register for this webinar to learn about the rationale behind choosing an assay format for total antibody (TAb) assays for AAV-based gene therapies, including the pros and cons of each format.

Speakers

Jim McNally, Ph.D., Chief Scientific Officer, BioAgilytix (Moderator)

Jay Stringer, Ph.D., Manager I, BioAgilytix

Luke Armstrong, Ph.D., Manager II, BioAgilytix

Todd Lester, Associate Director, BioAgilytix

Xiaoxi Yang, Ph.D., Manager I, BioAgilytix

See all Member Events